Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 92 articles:
HTML format
Text format



Single Articles


    July 2017
  1. MIYATA K, Yotsumoto F, Fukagawa S, Kiyoshima C, et al
    Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer.
    Anticancer Res. 2017;37:3955-3960.
    PubMed     Text format     Abstract available


  2. MURAKAMI M, Kagami S, Nguyen TT, Koi C, et al
    Expression of Polypeptide N-Acetylgalactosaminyltransferase-6 in Epithelial Ovarian Carcinoma.
    Anticancer Res. 2017;37:3911-3915.
    PubMed     Text format     Abstract available


  3. KURITA T, Thi TN, Koi C, Murakami M, et al
    Expression of N-Acetylgalactosaminyltransferase-6 Is Related to Expression of Cell Adhesion Molecules in Endometrial Cancer.
    Anticancer Res. 2017;37:3905-3910.
    PubMed     Text format     Abstract available


  4. FUKAGAWA S, Yotsumoto F, Odawara T, Manabe S, et al
    Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy.
    Anticancer Res. 2017;37:3891-3896.
    PubMed     Text format     Abstract available


  5. KUMAR A, Torres ML, Cliby WA, Kalli KR, et al
    Inflammatory and Nutritional Serum Markers as Predictors of Peri-operative Morbidity and Survival in Ovarian Cancer.
    Anticancer Res. 2017;37:3673-3677.
    PubMed     Text format     Abstract available


  6. UEDA T, Tsubamoto H, Inoue K, Sakata K, et al
    Itraconazole Modulates Hedgehog, WNT/beta-catenin, as well as Akt Signalling, and Inhibits Proliferation of Cervical Cancer Cells.
    Anticancer Res. 2017;37:3521-3526.
    PubMed     Text format     Abstract available


    June 2017
  7. OPRESCU DN, Bacalbasa N, Balescu I, Filipescu A, et al
    Urinary Tract Resections in Advanced-stage Cervical Cancer - A Series of Eight Cases.
    Anticancer Res. 2017;37:3271-3276.
    PubMed     Text format     Abstract available


  8. NA K, Kim EK, Jang W, Kim HS, et al
    CTNNB1 Mutations in Ovarian Microcystic Stromal Tumors: Identification of a Novel Deletion Mutation and the Use of Pyrosequencing to Identify Reported Point Mutation.
    Anticancer Res. 2017;37:3249-3258.
    PubMed     Text format     Abstract available


  9. MUALLEM MZ, Parashkevova A, Almuheimid J, Richter R, et al
    Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.
    Anticancer Res. 2017;37:3157-3161.
    PubMed     Text format     Abstract available


  10. HONDA KI, Asada R, Kageyama K, Fukuda T, et al
    Protein Complex of Fibrinogen Gamma Chain and Complement Factor H in Ovarian Cancer Patient Plasma.
    Anticancer Res. 2017;37:2861-2866.
    PubMed     Text format     Abstract available


  11. YAMAUCHI K, Afroze SH, Mitsunaga T, McCormick TC, et al
    3,4',7-O-trimethylquercetin Inhibits Invasion and Migration of Ovarian Cancer Cells.
    Anticancer Res. 2017;37:2823-2829.
    PubMed     Text format     Abstract available


  12. DIAB Y, Muallem MZ
    Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature.
    Anticancer Res. 2017;37:2809-2815.
    PubMed     Text format     Abstract available


    May 2017
  13. PRESL J, Ovesna P, Novotny Z, Vlasak P, et al
    Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.
    Anticancer Res. 2017;37:2697-2702.
    PubMed     Text format     Abstract available


  14. BACALBASA N, Balescu I, Marcu M, Oprescu DN, et al
    Solitary Splenic Metastasis After Surgically-treated Cervical Cancer - A Case Report and Literature Review.
    Anticancer Res. 2017;37:2615-2618.
    PubMed     Text format     Abstract available


  15. NA K, Park SY, Kim HS
    Clinicopathological Characteristics of Primary Ovarian Adenomyoma: A Single-institutional Experience.
    Anticancer Res. 2017;37:2565-2574.
    PubMed     Text format     Abstract available


  16. KIM JY, Na K, Kim HS
    Clinicopathological Characteristics of Mitotically-active Cellular Fibroma of the Ovary: A Single-institutional Experience.
    Anticancer Res. 2017;37:2557-2564.
    PubMed     Text format     Abstract available


  17. SLETTEN ET, Arnes M, Lysa LM, Moe BT, et al
    Prediction of Relapse After Therapy Withdrawal in Women with Endometrial Hyperplasia: A Long-term Follow-up Study.
    Anticancer Res. 2017;37:2529-2536.
    PubMed     Text format     Abstract available


  18. ALAVI S, Eckes L, Kratschell R, Taube ET, et al
    Pleomorphic Rhabdomyosarcoma of the Uterus - Case Report and a Systematic Review of the Literature.
    Anticancer Res. 2017;37:2509-2514.
    PubMed     Text format     Abstract available


  19. MUALLEM MZ, Henrich W, Braun T, Sehouli J, et al
    Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review.
    Anticancer Res. 2017;37:2487-2490.
    PubMed     Text format     Abstract available


  20. MAYER S, Gabriel B, Erbes T, Timme-Bronsert S, et al
    Cyr61 Expression Pattern and Association with Clinicopathological Factors in Patients with Cervical Cancer.
    Anticancer Res. 2017;37:2451-2456.
    PubMed     Text format     Abstract available


  21. NA K, Sung JY, Kim HS
    Stromal p16 Overexpression in Adult Granulosa Cell Tumors of the Ovary.
    Anticancer Res. 2017;37:2437-2444.
    PubMed     Text format     Abstract available


  22. HOLZMANN C, Koczan D, Loening T, Rommel B, et al
    Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22.
    Anticancer Res. 2017;37:2233-2237.
    PubMed     Text format     Abstract available


    April 2017
  23. BRADY PC, Soiffer RJ, Ginsburg ES
    Continuation of a Levonorgestrel Intrauterine Device During Hematopoietic Stem Cell Transplant: A Case Report.
    Anticancer Res. 2017;37:1985-1987.
    PubMed     Text format     Abstract available


  24. LEANDERSSON P, Granasen G, Borgfeldt C
    Ovarian Cancer Surgery - A Population-based Registry Study.
    Anticancer Res. 2017;37:1837-1845.
    PubMed     Text format     Abstract available


  25. PARK GB, Kim D
    PI3K Catalytic Isoform Alteration Promotes the LIMK1-related Metastasis Through the PAK1 or ROCK1/2 Activation in Cigarette Smoke-exposed Ovarian Cancer Cells.
    Anticancer Res. 2017;37:1805-1818.
    PubMed     Text format     Abstract available


  26. KLEJEWSKI A, Swierczewska M, Zaorska K, Brazert M, et al
    New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.
    Anticancer Res. 2017;37:1625-1636.
    PubMed     Text format     Abstract available


  27. HAYASHI T, Ichimura T, Kasai M, Sano K, et al
    Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination.
    Anticancer Res. 2017;37:1765-1772.
    PubMed     Text format     Abstract available


    March 2017

  28. Ovarian Cancers. Advances Through International Research Cooperation (GINECO, ENGOT, GCIG).
    Anticancer Res. 2017;37:1543-1544.
    PubMed     Text format    


  29. SEKIDO Y, Ohigashi S, Takahashi T, Hayashi N, et al
    Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
    Anticancer Res. 2017;37:1425-1431.
    PubMed     Text format     Abstract available


  30. GADDUCCI A, Barsotti C, Laliscia C, Cosio S, et al
    Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer: a Preliminary Analysis.
    Anticancer Res. 2017;37:1249-1255.
    PubMed     Text format     Abstract available


  31. DOGAN A, Schultheis B, Rezniczek GA, Hilal Z, et al
    Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature.
    Anticancer Res. 2017;37:969-978.
    PubMed     Text format     Abstract available


  32. VAN SN, Khac MN, Dimberg J, Matussek A, et al
    Prevalence of Cervical Infection and Genotype Distribution of Human Papilloma Virus Among Females in Da Nang, Vietnam.
    Anticancer Res. 2017;37:1243-1247.
    PubMed     Text format     Abstract available


    February 2017
  33. EL-BALAT A, Sanger N, Karn T, Becker S, et al
    IMP3 Expression in Borderline Tumors of the Ovary.
    Anticancer Res. 2017;37:583-588.
    PubMed     Text format     Abstract available


  34. TSUBAMOTO H, Inoue K, Sakata K, Ueda T, et al
    Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells.
    Anticancer Res. 2017;37:515-519.
    PubMed     Text format     Abstract available


    January 2017

  35. Early Nutrition and Lifestyle Factors. Effects on First Trimester Placenta.
    Anticancer Res. 2017;37:372-373.
    PubMed     Text format    


  36. RIZOU N, Moris D, Pikoulis E, Dimitrokallis N, et al
    Minimally Invasive Lymphadenectomy in Uterine Cervical Cancer: A Systematic Review.
    Anticancer Res. 2017;37:335-342.
    PubMed     Text format     Abstract available


  37. CHO O, Noh OK, Oh YT, Chang SJ, et al
    Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer.
    Anticancer Res. 2017;37:327-334.
    PubMed     Text format     Abstract available


  38. MURAKAMI T, Murata T, Kawaguchi K, Kiyuna T, et al
    Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.
    Anticancer Res. 2017;37:61-65.
    PubMed     Text format     Abstract available


    December 2016
  39. NICOLETTO MO, Casarin A, Baldoni A, Rulli E, et al
    Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.
    Anticancer Res. 2016;36:6541-6546.
    PubMed     Text format     Abstract available


  40. CHECK JH, Check D, Wilson C, Lofberg P, et al
    Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.
    Anticancer Res. 2016;36:6511-6513.
    PubMed     Text format     Abstract available


  41. SANTALA S, Talvensaari-Mattila A, Soini Y, Kuvaja P, et al
    Cyclins A, B, E and p27 in Endometrial Endometrioid Adenocarcinoma.
    Anticancer Res. 2016;36:6467-6473.
    PubMed     Text format     Abstract available


  42. ANASTASI E, Capoccia D, Granato T, Silecchia G, et al
    Implementing the Risk of Ovarian Malignancy Algorithm Adding Obesity as a Predictive Factor.
    Anticancer Res. 2016;36:6425-6429.
    PubMed     Text format     Abstract available


  43. LEE YY, Jeon HK, Lee J, Hong JE, et al
    Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells.
    Anticancer Res. 2016;36:6381-6388.
    PubMed     Text format     Abstract available


    November 2016
  44. STARBUCK KD, Drake RD, Budd GT, Rose PG, et al
    Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
    Anticancer Res. 2016;36:6161-6164.
    PubMed     Text format     Abstract available


  45. VINDEVOGEL E, Baert T, VAN Hoylandt A, Verbist G, et al
    The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer.
    Anticancer Res. 2016;36:5781-5792.
    PubMed     Text format     Abstract available


  46. LAPINSKA K, Housman G, Byler S, Heerboth S, et al
    The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells.
    Anticancer Res. 2016;36:5731-5742.
    PubMed     Text format     Abstract available


    October 2016
  47. JANSSEN S, Bajrovic A, Schild SE, Rades D, et al
    A Scoring Instrument to Predict the Survival Prognoses of Patients with Metastatic Epidural Spinal Cord Compression from Gynecological Malignancies.
    Anticancer Res. 2016;36:5469-5472.
    PubMed     Text format     Abstract available


  48. KOSKAS M, Depreeuw J, Moens S, Annibali D, et al
    Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.
    Anticancer Res. 2016;36:5381-5384.
    PubMed     Text format     Abstract available


  49. ROSENDAHL M, Mosgaard BJ, Hogdall C
    The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer.
    Anticancer Res. 2016;36:5373-5379.
    PubMed     Text format     Abstract available


  50. HILAL Z, Schultheis B, Hartmann F, Dogan A, et al
    What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature.
    Anticancer Res. 2016;36:5365-5371.
    PubMed     Text format     Abstract available


  51. COBEC IM, Sas I, Pirtea L, Cimpean AM, et al
    Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer.
    Anticancer Res. 2016;36:5265-5272.
    PubMed     Text format     Abstract available


  52. GUI H, Guo XR, Fang J, Ma SN, et al
    The Tumor-promoting Effects of FAM92A1-289 in Cervical Carcinoma Cells.
    Anticancer Res. 2016;36:5197-5204.
    PubMed     Text format     Abstract available


  53. BOUSSIOS S, Zarkavelis G, Seraj E, Zerdes I, et al
    Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies.
    Anticancer Res. 2016;36:5031-5042.
    PubMed     Text format     Abstract available


  54. HAYASHI T, Kawano M, Ichimura T, Ida K, et al
    Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma.
    Anticancer Res. 2016;36:4997-5007.
    PubMed     Text format     Abstract available


  55. NAPOLETANO C, Bellati F, Ruscito I, Pernice M, et al
    Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells.
    Anticancer Res. 2016;36:5109-5116.
    PubMed     Text format     Abstract available


    September 2016
  56. BERTELLI G, Drews F, Lutchman-Singh K
    Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in 'Real-world' Patients.
    Anticancer Res. 2016;36:4947-50.
    PubMed     Text format     Abstract available


  57. NASSER S, Almuheimid J, Plett H, Sehouli J, et al
    Feasibility and Safety of Laparoscopic Total Mesometrial Resection in Early-stage Cervical Cancer.
    Anticancer Res. 2016;36:4903-7.
    PubMed     Text format     Abstract available


  58. PHILIP CA, Pelissier A, Bonneau C, Hequet D, et al
    Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2016;36:4865-71.
    PubMed     Text format     Abstract available


  59. KIM EY, Jun KH, Jung JH, Jo YS, et al
    Laparoscopic Gastrectomy Followed by Chemotherapy for Advanced Gastric Cancer Diagnosed During Pregnancy: A Case Report.
    Anticancer Res. 2016;36:4813-6.
    PubMed     Text format     Abstract available


  60. DZIGGEL L, Janssen S, Bajrovic A, Veninga T, et al
    Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers.
    Anticancer Res. 2016;36:4777-80.
    PubMed     Text format     Abstract available


  61. MUALLEM MZ, Almuheimid J, Richter R, Braicu EI, et al
    Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Anticancer Res. 2016;36:4707-13.
    PubMed     Text format     Abstract available


  62. BODNER-ADLER B, Kimberger O, Schneidinger C, Kolbl H, et al
    Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix.
    Anticancer Res. 2016;36:4691-6.
    PubMed     Text format     Abstract available


  63. CAPLAKOVA V, Babusikova E, Blahovcova E, Balharek T, et al
    DNA Methylation Machinery in the Endometrium and Endometrial Cancer.
    Anticancer Res. 2016;36:4407-20.
    PubMed     Text format     Abstract available


  64. HILAL Z, Hartmann F, Dogan A, Cetin C, et al
    Lymphoma of the Cervix: Case Report and Review of the Literature.
    Anticancer Res. 2016;36:4931-40.
    PubMed     Text format     Abstract available


    August 2016
  65. AUMIPHIN J, Crochet P, Knight S, Carcopino X, et al
    Outcome and Follow-up of Patients with Endometrial Carcinoma Diagnosed on Operative Hysteroscopic Resection Specimens.
    Anticancer Res. 2016;36:4341-5.
    PubMed     Text format     Abstract available


  66. MUALLEM MZ, Dimitrova D, Pietzner K, Richter R, et al
    Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology. A NOGGO-AGO* survey of 144 Gynecological Departments in Germany.
    Anticancer Res. 2016;36:4227-32.
    PubMed     Text format     Abstract available


  67. MUALLEM MZ, Sehouli J, Almuheimid J, Richter R, et al
    Risk Factors of Lymph Nodes Metastases by Endometrial Cancer: A Retrospective One-center Study.
    Anticancer Res. 2016;36:4219-25.
    PubMed     Text format     Abstract available


  68. PIMENTEL C, Becquet M, Lavoue V, Henno S, et al
    Ovarian Metastases from Breast Cancer: A Series of 28 Cases.
    Anticancer Res. 2016;36:4195-200.
    PubMed     Text format     Abstract available


  69. LOZNEANU L, Pinciroli P, Ciobanu DA, Carcangiu ML, et al
    Computational and Immunohistochemical Analyses Highlight AXL as a Potential Prognostic Marker for Ovarian Cancer Patients.
    Anticancer Res. 2016;36:4155-63.
    PubMed     Text format     Abstract available


  70. COIMBRA EC, DA Conceicao Gomes Leitao M, Junior MR, DE Oliveira TH, et al
    Expression Profile of MicroRNA-203 and its DeltaNp63 Target in Cervical Carcinogenesis: Prospects for Cervical Cancer Screening.
    Anticancer Res. 2016;36:3939-46.
    PubMed     Text format     Abstract available


    July 2016
  71. MIYAHARA D, Katsuta T, Maehara M, Takahashi Y, et al
    Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer.
    Anticancer Res. 2016;36:3725-9.
    PubMed     Text format     Abstract available


  72. HASHIMOTO K, Honda K, Matsui H, Nagashima Y, et al
    Flow Cytometric Analysis of Ovarian Cancer Ascites: Response of Mesothelial Cells and Macrophages to Cancer.
    Anticancer Res. 2016;36:3579-84.
    PubMed     Text format     Abstract available


  73. CHO O, Chun M, Chang SJ, Oh YT, et al
    Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Anticancer Res. 2016;36:3541-7.
    PubMed     Text format     Abstract available


  74. GADDUCCI A, Cosio S, Fanucchi A, Tana R, et al
    Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy.
    Anticancer Res. 2016;36:3477-82.
    PubMed     Text format     Abstract available


  75. OISHI S, Kudaka W, Toita T, Ariga T, et al
    Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.
    Anticancer Res. 2016;36:3471-5.
    PubMed     Text format     Abstract available


  76. SCHRODER L, Rudlowski C, Kutkuhn P, Abramian A, et al
    Impact of Open Laparoscopy in Patients Under Suspicion of Ovarian Cancer.
    Anticancer Res. 2016;36:3459-64.
    PubMed     Text format     Abstract available


  77. BOUNOUS VE, Ferrero A, Fuso L, Ravarino N, et al
    Endometriosis-associated Ovarian Cancer: A Distinct Clinical Entity?
    Anticancer Res. 2016;36:3445-9.
    PubMed     Text format     Abstract available


  78. PYLVAS-EEROLA M, Liakka A, Puistola U, Koivunen J, et al
    Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer.
    Anticancer Res. 2016;36:3425-31.
    PubMed     Text format     Abstract available


  79. STOPE MB, Hettenbach D, Kaul A, Paditz M, et al
    The Tumor Suppressor MicroRNA-1 Exhibits Restricted Inhibition of Proliferation of Ovarian Cancer Cells.
    Anticancer Res. 2016;36:3329-34.
    PubMed     Text format     Abstract available


  80. STOPE MB, Wiegank L, Weiss M, Diesing K, et al
    Drug-induced Modulation of Heat Shock Protein HSPB1 in an Ovarian Cancer Cell Model.
    Anticancer Res. 2016;36:3321-7.
    PubMed     Text format     Abstract available


    June 2016
  81. KOLBL AC, Wellens R, Koch J, Rack B, et al
    Endometrial Adenocarcinoma: Analysis of Circulating Tumour Cells by RT-qPCR.
    Anticancer Res. 2016;36:3205-9.
    PubMed     Text format     Abstract available


  82. STIASNY A, Kuhn C, Mayr D, Alexiou C, et al
    Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.
    Anticancer Res. 2016;36:3195-8.
    PubMed     Text format     Abstract available


  83. FREIER CP, Stiasny A, Kuhn C, Mayr D, et al
    Immunohistochemical Evaluation of the Role of p53 Mutation in Cervical Cancer: Ser-20 p53-Mutant Correlates with Better Prognosis.
    Anticancer Res. 2016;36:3131-7.
    PubMed     Text format     Abstract available


  84. BACALBASA N, Balescu I, Dima S, Popescu I, et al
    Hepatic Resection for Liver Metastases from Cervical Cancer Is Safe and May Have Survival Benefit.
    Anticancer Res. 2016;36:3023-7.
    PubMed     Text format     Abstract available


  85. NAKAMURA K, Nakayama K, Ishikawa M, Katagiri H, et al
    High Pre-treatment Plasma D-Dimer Level as a Potential Prognostic Biomarker for Cervical Carcinoma.
    Anticancer Res. 2016;36:2933-8.
    PubMed     Text format     Abstract available


  86. PILKA R, Marek R, Adam T, Kudela M, et al
    Systemic Inflammatory Response After Open, Laparoscopic and Robotic Surgery in Endometrial Cancer Patients.
    Anticancer Res. 2016;36:2909-22.
    PubMed     Text format     Abstract available


  87. CACAN E
    Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells.
    Anticancer Res. 2016;36:2819-26.
    PubMed     Text format     Abstract available


  88. ARZUMAN L, Beale P, Yu JQ, Huq F, et al
    Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines.
    Anticancer Res. 2016;36:2809-18.
    PubMed     Text format     Abstract available


    April 2016
  89. TANAKAYA K, Yamaguchi T, Ishikawa H, Hinoi T, et al
    Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome.
    Anticancer Res. 2016;36:1985-9.
    PubMed     Text format     Abstract available


  90. LALISCIA C, Fabrini MG, Delishaj D, Coraggio G, et al
    Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study.
    Anticancer Res. 2016;36:1885-9.
    PubMed     Text format     Abstract available


    March 2016
  91. KACPERCZYK J, Bartnik P, Romejko-Wolniewicz E, Jalinik K, et al
    Results of Further Diagnostic Procedures Among Patients with Cytological Characteristics of Minor Changes on Pap Smears.
    Anticancer Res. 2016;36:1023-6.
    PubMed     Text format     Abstract available


    January 2016
  92. LALISCIA C, Gadducci A, Montrone S, Tana R, et al
    Radiotherapy as Definitive Treatment of Patients with Primary Vulvar Carcinoma Unfit for Surgery and with Recurrent Vulvar Carcinoma After Primary Radical Surgery: Results of a Retrospective Single-center Study.
    Anticancer Res. 2016;36:387-91.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: